Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
From left: Katherine Mast Hagemann, B.S.N., RN, and Dr. Andrew KuykendallThe present atmosphere in oncology (and medication on the whole) incentivizes hurried, impersonal...
Recap of each FDA approval introduced by the regulatory company within the month of Could 2025, spanning varied most cancers sorts.Throughout the month...
Iopofosine-131 acquired FDA breakthrough standing for relapsed or refractory Waldenstrom macroglobulinemia, displaying robust response charges in early trials.The U.S. Meals and Drug Administration...
